Status:

NOT_YET_RECRUITING

Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System

Lead Sponsor:

Sue Peters

Collaborating Sponsors:

Pacira Pharmaceuticals, Inc

Conditions:

Spasticity as Sequela of Stroke

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Spasticity can make regular daily activities difficult or impossible. Cryoneurolysis is a new technique to treat spasticity that is currently being tested. For this technique, a needle is inserted alo...

Detailed Description

Spasticity is the result of an overactive stretch reflex after an upper motor neuron injury that results in affected muscles being constantly, involuntarily contracted.1 A failure to treat spasticity ...

Eligibility Criteria

Inclusion

  • are a patient at Parkwood Institute
  • have increased range of motion or reduced spasticity with diagnostic nerve block,
  • have no undesired loss of function with a diagnostic nerve block,
  • score 2 or higher in the Modified Ashworth scale,
  • have at least flickers of movement in the upper extremity,
  • have not received botulinum-A neurotoxin within the past 3 months, and
  • they can understand and follow instructions in English.

Exclusion

  • have contraindications to TMS (i.e., history of seizure, pregnancy) or 3T MRI (i.e., certain metallic implants),
  • are unable to provide informed consent (i.e., severe cognitive impairment),
  • receive any antispastic medication (oral, intrathecal, or otherwise) over the course of the follow-up period
  • receive any toxin injections for spasticity (Botulinum-A Toxin or equivalent) within 3 months of initial baseline assessments or at any time over the course of the follow-up period.
  • Have previously undergone any nerve-specific interventions (phenol neurolysis, radio-frequency ablation, or cryoneurolysis) for spasticity on a nerve that will be targeted for this study.

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2028

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT06958289

Start Date

May 1 2025

End Date

May 1 2028

Last Update

May 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Parkwood Institute

London, Ontario, Canada, N6C 0A7